Another study reported a clinical trial of a biepitope-targeting CAR against BCMA (LCAR-B38M), in which five R/R MM patients with extramedullary infiltration experienced tumor disappearance after CAR T cell therapy. This evidence concerns the gene TNFRSF17 and neoplasm.